Parkin Gene Alterations in Hepatocellular Carcinoma

Genes Chromosomes and Cancer

Volumn 40, Issue 2, 2004, Pages 85-96

  Wang, Fang ^a   Denison, Stacy ^a   Lai, Jin Ping ^a   Philips, Leslie A ^a   Montoya, Damien ^a   Kock, Norman ^b   Schüle, Birgitt ^c   Klein, Christine ^b   Shridhar, Viji ^a   Roberts, Lewis R ^a   Smith, David I ^a,d  

^a Mayo Clinic College of Medicine   (United States)

^b UNIVERSITY OF LÜBECK   (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PARKIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; FRA6E GENE; GENE; GENE DELETION; GENE MUTATION; GENETIC TRANSFECTION; HEP3B GENE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR STABILITY; PARKIN GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CHROMOSOME DELETION; DNA, NEOPLASM; EXONS; GENE DOSAGE; GENES, TUMOR SUPPRESSOR; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSFECTION; TUMOR CELLS, CULTURED; UBIQUITIN-PROTEIN LIGASES;

EID: 2342468174     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20020     Document Type: Article

References (38)

1. Becker NA, Thorland EC, Denison SR, Phillips LA, Smith DI. 2002. Evidence that instability within the FRA3B region extends four megabases. Oncogene 21:8713-8722.
2. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. 2000. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60:2140-2145.
3. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J. 1999. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 59:5270-5274.
4. Brenner C. 2002. Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry 41:9003-9014.
5. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 100:5956-5961.
6. Chang NS. 2002. A potential role of p53 and WOX1 in mitochondrial apoptosis (review). Int J Mol Med 9:19-24.
7. Chang NS, Doherty J, Ensign A. 2003. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem 278:9195-9202.
8. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI. 2003a. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 38:40-52.
9. Denison SR, Wang F, Mueller B, Kock N, Phillips LA, Klein C, Smith DI. 2003b. Genetic alteration in the common fragile site gene PARK2 in ovarian and other cancers. Oncogene 22:8370-8378.
10. Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E. 2002. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oneogene 21:1832-1840.
11. Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TP. 2000. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 60: 18-21.
12. Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, Brookes AJ, Yamamura Y, Kobayashi T, Wang M, Yoritaka A, Minoshima S, Shimizu N, Mizuno Y. 1998. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. Biochem Biophys Res Commun 249:754-758.
13. Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. 2001. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 10:1649-1656.
14. Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H, Pramstaller PP, Schwinger E, Bressman SB, Fahn S, Klein C. 2002. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 58:1239-1246.
15. Huebner K, Croce CM. 2003. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer 88:1501-1506.
16. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. 1999. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59:3333-3339.
17. Kahkonen M. 1988. Population cytogenetics of folate-sensitive fragile sites. I. Common fragile sites. Hum Genet 80:344-348.
18. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
19. Kitay-Cohen Y, Amiel A, Ashur Y, Fejgin MD, Herishanu Y, Afanasyev F, Bomstein Y, Lishner M. 2001. Analysis of chromosomal aberrations in large hepatocellular carcinomas by comparative genomic hybridization. Cancer Genet Cytogenet 131:60-64.
20. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162.
21. Kuroda Y, Mitsui T, Akaike M, Azuma H, Matsumoto T. 2001. Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism. J Neurol Neurosurg Psychiatry 71: 231-234.
22. Lee SH, Kim WH, Kim HK, Woo KM, Nam HS, Kim HS, Kim JG, Cho MH. 2001. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 284:850-855.
23. Mangelsdorf M, Ried K, Woollatt E, Dayan S, Eyre H, Finnis M, Hobson L, Nancarrow J, Venter D, Baker E, Richards RI. 2000. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res 60:1683-1689.
24. Michels VV. 1985 Fragile sites on human chromosomes: description and clinical significance. Mayo Clin Proc 60:690-696.
25. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597.
26. Periquet M, Lucking C, Vaughan J, Bonifati V, Durr A, De Michele G, Horstink M, Farrer M, Illarioshkin SN, Pollak P, Borg M, Brefel-Courbon C, Denefle P, Meco G, Gasser T, Breteler MM, Wood N, Agid Y, Brice A. 2001. Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. Am J Hum Genet 68:617-626.
27. Rao PN, Heerema NA, Palmer CG. 1988. Fragile sites induced by FUdR, caffeine, and aphidicolin. Their frequency, distribution, and analysis. Hum Genet 78:21-26.
28. Rawal N, Periquet M, Lohmann E, Lucking CB, Teive HA, Ambrosio G, Raskin S, Lincoln S, Hattori N, Guimaraes J, Horstink MW, Dos Santos Bele W, Brousolle E, Destee A, Mizuno Y, Farrer M, Deleuze JF, De Michele G, Agid Y, Durr A, Brice A. 2003. New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism. Neurology 60:1378-1381.
29. Ren Y, Zhao J, Feng J. 2003. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 23: 3316-3324.
30. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, Sozzi G. 1999. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 96:8489-8492.
31. Smith DI, Huang H, Wang L. 1998. Common fragile sites and cancer (review). Int J Oncol 12:187-196.
32. Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J, Langston JW. 2003. Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov Disord 18:758-763.
33. Verma R, Babu A. 1995. Human chromosomes: principles and techniques. New York: McGraw-Hill.
34. Yakicier MC, Legoix P, Vaury C, Gressin L, Tubacher E, Capron F, Bayer J, Degott C, Balabaud C, Zucman-Rossi J. 2001. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene 20:5232-5238.
35. Yendamuri S, Kuroki T, Trapasso F, Henry AC, Dumon KR, Huebner K, Williams NN, Kaiser LR, Croce CM. 2003. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 63:878-881.
36. Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC. 2000. Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res 60:1049-1053.
37. Zhao J, Ren Y, Jiang Q, Feng J. 2003. Parkin is recruited to the centrosome in response to inhibition of proteasomes. J Cell Sci 116:4011-4019.
38. Zhao P, Song X, Nin YY, Lu YL, Li XH. 2003. Loss of fragile histidine triad protein in human hepatocellular carcinoma. World J Gastroenterol 9:1216-1219.